1 in 10 patients prescribed an opioid within 7 days of surgery will become a long-time user. Postoperative patients who experience an adverse drug event will result in an average longer stay, up to 47% higher cost of care, and have a significantly higher risk of admission within 30 days. CQuentia provides a comprehensive, industry leading Pharmacogenomic (PGx) test that has been shown to reduce adverse gene-drug, drug-drug, and drug-disease events.
Pharmacogenomic (PGx) Testing helps uncover the biological reasons behind different outcomes to medications by linking genetic variability to drug responses and outcomes. By utilizing PGx testing, pain management providers can devise individualized pain management regiments to alleviate acute and chronic pain and simultaneously reduce narcotics use. PGx testing has been shown to reduce narcotic use by 50%, increase medication adherence and reduce ED visits by approximately 70%.
Find out what other leading institutions are saying about CQuentia.
CQuentia’s goal is to deliver actionable information, integrated at the point-of-care to help you deliver the individualized pain management regimen for your patients. Our PGx tests are developed incorporating the guidelines laid by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in our CLIA-certified laboratory. We have taken our innovative technology and integrated within EMR into some of the largest hospital systems in the country.
Contact us to enlist your institution in a no-risk trial of our PGx program and be our partner in improving global health care by accelerating the impact of genomics on patient care.
CQuentia, more than a lab, more than a test. The leaders in the new frontier of genomic testing and personalized medicine.